Why the study?
Does lisinopril reduce urinary MCP-1 and improve renal function in patients with type 2 diabetes and diabetic nephropathy?
Does lisinopril reduce urinary MCP-1 and improve renal function in patients with type 2 diabetes and diabetic nephropathy?
ACE inhibitor therapy reduces urinary MCP-1 levels in patients with diabetic nephropathy, suggesting a mechanism for its anti-fibrotic and renoprotective effects.
No takes yet. Share an insight, caveat, or question.
May support MCP-1 as a renoprotective mechanism of ACE inhibition in diabetic nephropathy; leaves open causality pending randomized confirmation.
Amann et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: